Important regulatory notice. Tirzepatide (Mounjaro) is an MHRA-licensed prescription medicine in the United Kingdom. This page is a research-context summary of cardiovascular observations reported in the published clinical literature. It is not medical advice. Anyone taking tirzepatide should discuss any clinical question with their prescribing clinician.
Quick research summary. The published cardiovascular literature for the GLP-1 receptor agonist class describes a complex picture: cardiometabolic markers (weight, glycated haemoglobin, blood pressure, lipid panel) generally trend favourably in registration trials, while a smaller heart-rate signal has been described and is included in the licensed product information. The MHRA-approved Summary of Product Characteristics (SmPC) for tirzepatide is the authoritative UK reference.
What the licensed Summary of Product Characteristics covers
The tirzepatide SmPC, published on the electronic Medicines Compendium at emc.medicines.org.uk, lists the cardiovascular and other adverse-event categories reported in the registration programme and post-marketing surveillance, with regulator-defined frequencies. This is the appropriate source of truth for any UK clinical question.
Wider GLP-1 cardiovascular literature
The cardiovascular outcomes literature for the GLP-1 receptor agonist class includes large outcome trials in tirzepatide and related compounds. Cardiometabolic risk markers (weight, HbA1c, blood pressure, lipid panel) typically trend favourably in registration data, while a small heart-rate increase signal is described in the class. Specific cardiovascular outcome data for tirzepatide is part of the regulator dossier and is summarised in the SmPC and the wider published literature on the SURPASS and SURMOUNT programmes.
If you are taking tirzepatide
Speak to your prescribing clinician about any cardiovascular symptoms or concerns. The Yellow Card Scheme at yellowcard.mhra.gov.uk is the UK reporting route for suspected adverse drug reactions and can be used by patients as well as healthcare professionals.
Frequently Asked Questions
Where is the authoritative tirzepatide safety information?
The MHRA-approved Summary of Product Characteristics on emc.medicines.org.uk and the Patient Information Leaflet supplied with the product.
Has tirzepatide been studied in cardiovascular outcome trials?
Cardiovascular outcomes are part of the wider GLP-1 receptor agonist clinical evidence base, with class and compound-specific data published in the peer-reviewed literature and indexed on PubMed.
How do I report a suspected side effect?
Through the Yellow Card Scheme at yellowcard.mhra.gov.uk.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. We do not supply tirzepatide for human use; tirzepatide is a prescription-only medicine in the United Kingdom and is available from registered prescribers and licensed pharmacies.
